Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
Stocks mentioned in the article
ChangeLast1st jan.
SANOFI 0.93% 68.39 Delayed Quote.-5.89%
SANOFI 0.95% 68.31 Real-time Quote.-4.41%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
04:49pSANOFI : New study on Dengvaxia ill-effects boosts demand for full refund
AQ
02:34pSANOFI : Completes Its Acquisition of Ablynx Following Expiration of Squeeze-Out..
AQ
08:02aLatecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19SANOFI : Recipharm buys Sanofi CMO site in UK, signs long-term supply deal
AQ
06/19EVOTEC : and Sanofi Sign Definitive Agreement to Combat Infectious Diseases
AQ
06/19SANOFI : Evotec says Sanofi deal makes it anti-infectives powerhouse
AQ
06/19PEUGEOT : Sanofi poaches former PSA finance boss Chasseloup de Chatillon
RE
06/19Sanofi Names Jean-Baptiste Chasseloup de Chatillon as CFO, Executive VP
DJ
06/19SANOFI : appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President..
AQ
06/19SANOFI : appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President..
GL
More news
News from SeekingAlpha
06/19Translate Bio Prepares For $100 Million U.S. IPO 
06/19Merger Arbitrage Mondays - June 18, 2018 
06/19Sanofi transfers infectious disease unit to Evotec 
06/19Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice Presiden.. 
06/16STOCKS TO WATCH : Don't Sleep On Vienna 
Financials (€)
Sales 2018 35 273 M
EBIT 2018 8 334 M
Net income 2018 5 099 M
Debt 2018 15 707 M
Yield 2018 4,46%
P/E ratio 2018 16,28
P/E ratio 2019 15,21
EV / Sales 2018 2,86x
EV / Sales 2019 2,71x
Capitalization 85 245 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 77,0 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-4.41%98 673
JOHNSON & JOHNSON-13.17%325 398
PFIZER-0.17%211 520
NOVARTIS-8.25%188 977
ROCHE HOLDING LTD.-14.38%182 331
MERCK AND COMPANY8.46%164 082